SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?


To: synchro who wrote (1956)5/4/1998 9:14:00 AM
From: Scott H. Davis  Respond to of 4676
 
Isis Completes Follow-On Private Financing; Additional $15 Million Totals $40 Million Raised

biz.yahoo.com



To: synchro who wrote (1956)5/4/1998 9:16:00 AM
From: Scott H. Davis  Respond to of 4676
 
I have not noticed all these indications before - have I missed something or is there something new here? Scott

<ISIS 2302, an inhibitor of ICAM-1, is in a pivotal quality trial for Crohn's disease, Phase II clinical trials for renal transplant rejection, rheumatoid arthritis and ulcerative colitis, and is being explored as a topical administration for psoriasis and an aerosol administration for asthma>